CMND-100 Shows Clean Safety Profile Across All Doses in FDA Trial
CMND is trading near its 52-week low of $1.43 (3.5% above the low).
Summary
Clearmind's CMND-100 met its primary safety endpoint in Part A of the Phase I/II trial, with no serious adverse events across four dose cohorts up to 160 mg. The drug demonstrated consistent tolerability throughout full dose escalation in the FDA-regulated clinical trial. This is the first readout of actual safety data—prior updates only confirmed dosing completion. The clean tolerability profile de-risks the non-hallucinogenic neuroplastogen approach and supports advancement into Part B with AUD patients. However, the company's micro-cap status and recent heavy dilution from convertible notes temper the impact. The stock trades near its 52-week low of $1.43, reflecting ongoing financing overhang.
At the time of this announcement, CMND was trading at $1.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $1.43 to $524.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.